Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06171724 · ClinicalTrials.gov registry record · Early Phase 1
Ashwagandha Pharmacokinetics Study in Older Adults
A Early Phase 1 study, sponsored by Oregon Health and Science University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT06171724: Clinical Trial Early Phase 1 study, sponsored by Oregon Health and Science University.
NCT06171724 is a Early Phase 1 study that was terminated before completion, run by Oregon Health and Science University. The registered enrollment target is 11 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06171724, a Early Phase 1 study, was terminated before completion, sponsored by Oregon Health and Science University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will measure the oral bioavailability and pharmacokinetics of known compounds from a standardized Withania somnifera botanical dietary supplement in healthy older adults.
Primary Outcome
After oral administration of Shoden (240 or 480 mg), plasma concentrations of withanolides will be measured in plasma samples obtained over a 48-hour period, using liquid chromatography coupled to multiple reaction monitoring mass spectrometry (LC-MRM-MS) to determine pharmacokinetic parameters.
Interventions
- DIETARY_SUPPLEMENT Shoden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2024-04-08 |
| Est. Completion | 2024-12-09 |
| Phase | Early Phase 1 |
Why NCT06171724 stopped before completion
NCT06171724 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 1 intervention - of which Shoden is the first listed.
NCT06171724 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06171724 about?
NCT06171724 is a clinical study titled "Ashwagandha Pharmacokinetics Study in Older Adults". This study will measure the oral bioavailability and pharmacokinetics of known compounds from a standardized Withania somnifera botanical dietary supplement in healthy older adults.
What is the current status of trial NCT06171724?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2024-04-08. Estimated completion is 2024-12-09.
What interventions are being tested in trial NCT06171724?
The interventions under investigation include: Shoden (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06171724?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06171724's enrollment target sits among peer trials
11 1600th of 2000 higher than 373 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI